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The c-Jun NH2-terminal kinase (JNK) signaling
pathway has been implicated in the development of
tumor necrosis factor (TNF)-dependent hepatitis.
JNK may play a critical role in hepatocytes during
TNF-stimulated cell death in vivo. To test this hypoth-
esis, we examined the phenotype of mice with
compound disruption of the Jnk1 and Jnk2 genes.
Mice with loss of JNK1/2 expression in hepatocytes
exhibited no defects in the development of hepatitis
compared with control mice, whereas mice with
loss of JNK1/2 in the hematopoietic compartment ex-
hibited a profound defect in hepatitis that was associ-
ated with markedly reduced expression of TNF-a.
These data indicate that JNK is required for TNF-a
expression but not for TNF-a-stimulated death of
hepatocytes. Indeed, TNF-a induced similar hepatic
damage in both mice with hepatocyte-specific
JNK1/2 deficiency and control mice. These observa-
tions confirm a role for JNK in the development of
hepatitis but identify hematopoietic cells as the site
of the essential function of JNK.
INTRODUCTION
Tumor necrosis factor (TNF) is an inflammatory cytokine that
exerts multiple biological activities on target tissues, including
cell survival, cell proliferation, and cell death. The consequence
of cellular exposure to TNF reflects the opposing actions of
signaling pathways that are activated by cell surface TNF recep-
tors, including nuclear factor kB (NF-kB), mitogen-activated
protein (MAP) kinases, and caspases (Chen and Goeddel, 2002).
The type 1 TNF receptor (TNFR1)mediates signal transduction
by recruiting proteins that assemble on the cytoplasmic tail of the
receptor, including the scaffold protein TRADD, the protein
kinase RIP1, and TRAF2/5 adaptor proteins (Micheau and
Tschopp, 2003). This complex signals the activation of NF-kB
andMAP kinase pathways, is transiently assembled, and subse-
quently dissociates from the cytoplasmic tail of the receptor. Asecond complex is then formed by the TRADD scaffold protein
together with RIP1, the adaptor protein FADD, cFLIP, and pro-
caspase 8 (Micheau and Tschopp, 2003). This complex activates
caspase 8 and promotes apoptosis. The strength of caspase 8
signaling is regulated, in part, by the level of NF-kB-dependent
expression of the pseudocaspase cFLIP that functions as an
inhibitor of pro-caspase 8 activation (Thome and Tschopp,
2001). TNF-a-induced caspase 8 activation can also be medi-
ated after mitochondrial outer membrane permeabilization by
Smac-induced degradation of cIAP1/2, CYLD-dependent
release of RIP1 from the cytoplasmic tail of TNFR1, and the
subsequent formation of a RIP1 complex with FADD and
caspase 8 (Wang et al., 2008).
The type 2 TNF receptor (TNFR2) functions together with
TNFR1, in part, by recruiting the E3 ligase c-IAP1 that can ubiq-
uitinate and degrade c-IAP2 and the adaptor protein TRAF2
(Chan and Lenardo, 2000; Conze et al., 2005; Fotin-Mleczek
et al., 2002; Li et al., 2002; Wu et al., 2005). TNFR2 potentiates
TNFR1-stimulated cell death by blocking TRAF2-mediated acti-
vation of antiapoptotic signaling by NF-kB and MAP kinases.
Indeed, cell surface TNF-a, which binds both TNFR1 and
TNFR2, is a more potent inducer of cell death than soluble
TNF-a, which preferentially binds TNFR1 (Eissner et al., 1995;
Grell et al., 1995, 1998).
JNK represents one of the MAP kinases activated by TNFR1.
The mechanism of JNK regulation is mediated by the TRAF2/5
adaptor proteins that cause ubiquitin-dependent activation of
the MAP kinase kinase kinase TAK1 that phosphorylates and
activates the MAP kinase kinase MKK7, which, in turn, phos-
phorylates and activates JNK (Adhikari et al., 2007; Sato et al.,
2005; Shim et al., 2005; Tournier et al., 2001). This TRAF-medi-
ated activation of JNK is transient. A sustained phase of JNK
activation, observed at later times, might be mediated by
a TNF-induced complex of TRADD, RIP1, NOX1, and RAC1
(Kim et al., 2007) that causes accumulation of reactive oxygen
species (ROS) and activation of the JNK pathway (Sakon et al.,
2003) by increasing ASK1 activity (Tobiume et al., 2001) and
decreasing phosphatase activity (Kamata et al., 2005). This
second and sustained phase of TNF-stimulated JNK activation
is negatively regulated by NF-kB (De Smaele et al., 2001;
Reuther-Madrid et al., 2002; Tang et al., 2001) by suppression
of ROS accumulation (Pham et al., 2004; Sakon et al., 2003).Cell 136, 249–260, January 23, 2009 ª2009 Elsevier Inc. 249
The two phases of TNF-stimulated JNK activation appear to
mediate different cellular responses (Ventura et al., 2006). The
initial transient phase of TRAF-mediated JNK activation might
signal cell survival (Lamb et al., 2003) and the later sustained
phase of JNK activation might contribute to ROS-induced cell
death (Ventura et al., 2004). The exact role of TNF-stimulated
JNK in the regulation of cell survival and/or death has been
controversial (Varfolomeev and Ashkenazi, 2004). Studies of
cultured fibroblasts demonstrate that compound mutation of
the Jnk1 and Jnk2 genes does not prevent TNF-stimulated
apoptosis (Lamb et al., 2003), but JNK1/2-deficient fibroblasts
do exhibit defects in the TNF-induced accumulation of cytotoxic
ROS (Ventura et al., 2004).However, these studies employedarti-
ficial cell culture conditions (inhibition of transcription, transla-
tion, orNF-kB) to enable TNF-stimulated cell death. Theseproce-
dureswere necessary because treatment of wild-type fibroblasts
with TNF alone does not cause cell death. This analysis illustrates
the need for better methods to study TNF-induced cell death that
are not dependent on the use of artificial cell culture conditions.
It has been reported that TNF-induced cell death can be
studied using mouse models of hepatitis. For example, treat-
ment of micewith the lectin concanavalin A (Con A) causes fulmi-
nant hepatitis in wild-type mice (Tiegs et al., 1992). Liver cell
death in this model is TNF dependent because Con A causes
greatly reduced hepatitis in both Tnfr1/ and Tnfr2/ mice
(Kusters et al., 1997; Maeda et al., 2003). Furthermore, Con
A-induced hepatitis requires membrane-bound TNF-a, but not
soluble TNF-a (Kusters et al., 1997). This form of hepatitis has
been reported to require JNK (Chang et al., 2006; Kamata
et al., 2005;Maeda et al., 2003). Themechanism of JNK signaling
might be mediated by phosphorylation and activation of the E3
ligase Itch that can ubiquitinate and degrade the caspase 8
antagonist cFLIP (Chang et al., 2006). This function of JNK in
TNF-stimulated cell death is consistent with several reports
that have implicated an essential role of JNK in TNF-stimulated
apoptosis of tumor cell lines (Deng et al., 2003; Verheij et al.,
1996), fibroblasts (Dietrich et al., 2004; Liu et al., 2004), and
hepatocytes (Chang et al., 2006; Kamata et al., 2005; Maeda
et al., 2003; Wang et al., 2006), but is inconsistent with other
reports that suggest a nonessential role of JNK in TNF-stimu-
lated cell death (Hochedlinger et al., 2002; Lamb et al., 2003;
Liedtke et al., 2002; Liu et al., 1996; Natoli et al., 1997).
The purpose of this study was to examine the role of JNK in
TNF-mediated hepatitis using compound mutant mice with
defects in both of the ubiquitously expressed genes that encode
JNK isoforms. Our analysis demonstrates that JNK is essential
for hepatitis. We show that JNK in hematopoietic cells is critically
required for TNF-a expression and that JNK is not required for
TNF-a-stimulated cell death during the development of hepatitis.
RESULTS
Examination of Hepatitis in Mice Deficient
of JNK1 or JNK2
It has been reported that Jnk1/ mice and Jnk2/ mice exhibit
a major defect in Con A-induced hepatitis (Maeda et al., 2003),
although subsequent studies have reported a primary role
played by JNK1 (Chang et al., 2006; Kamata et al., 2005). We250 Cell 136, 249–260, January 23, 2009 ª2009 Elsevier Inc.tested the effect of Con A-induced hepatitis on wild-type,
Jnk1/, and Jnk2/ mice (see Figure S1 available online).
Con A caused similar hepatic damage in wild-type and JNK-
knockout mice (Figures S1A and S2A). Serum transaminase
activity, a hallmark of hepatic injury, was modestly reduced in
both Jnk1/ mice and Jnk2/ mice compared with wild-type
mice, but the differences were not statistically significant
(Figure S1B). The effects of Con A on hepatic injury are thought
to bemediated by induced cytokine expression. Similar amounts
of serum cytokines were detected in the wild-type and knockout
mice, although a selective loss of interleukin-1 expression was
found in Jnk1/ mice (Figure S1C). Together, these data
suggest that JNK1 and JNK2 do not play a major role in Con
A-stimulated hepatitis. Nevertheless, it is possible that JNK
plays a role because studies using a different model of murine
hepatitis (treatment with lipopolysaccharide [LPS]) did show
that both Jnk1/ mice and Jnk2/ mice exhibited a partial
reduction in hepatic damage that was confirmed by histological
analysis of liver sections (Figures S2B and S3A), measurement of
serum transaminase activity (Figure S3B), and decreased
expression of serum cytokines, including TNF-a and interferon-
g (IFN-g) (Figure S3C).
Examination of Hepatitis in Compound Mutant
Jnk1/ Jnk2/ Mice
Our analysis of hepatitis in Jnk1/ mice and Jnk2/ mice indi-
cated that JNK1 and JNK2 might contribute to the disease
process (Figures S1–S3). However, the roles of JNK1 and
JNK2 are unclear because we found that Jnk1/ mice and
Jnk2/ mice did not demonstrate defects in Con A-induced
hepatitis (Figure S1). These observations suggested the possi-
bility that JNK1 and JNK2 play redundant roles during the devel-
opment of hepatitis (Figure S4). To test this hypothesis, we
examined the effect of Con A in mice with compound disruption
of both the Jnk1 and Jnk2 genes. Because Jnk1/ Jnk2/mice
die during early embryonic development (Kuan et al., 1999), we
employed a conditional gene ablation strategy.
Efficient deletion of floxed alleles in both the liver and hemato-
poietic cells can be achieved in Mx1-Cre transgenic mice when
these mice are treated with polyinosinic-polycytidylic acid
(poly-IC) (Kuhn et al., 1995). We therefore treated Mx1-Cre+
(control) mice and Mx1-Cre+ Jnk1f/f Jnk2/ mice with poly-IC
(Figure 1). Deletion of floxed Jnk1 (Jnk1D/D) was confirmed by
polymerase chain reaction (PCR) analysis of genomic DNA.
JNK protein was not detected in the liver of the compound
mutant mice by immunoblot analysis (Figure 1A). Treatment of
these mice with Con A demonstrated that the JNK1/2-deficient
mice exhibited strong protection against hepatitis when exam-
ined by histological analysis of liver sections (Figures 1B and
S2C) ormeasurement of serum transaminase activity (Figure 1C).
The JNK1/2-deficient mice also exhibited reduced mortality
compared with control mice in response to the Con A challenge
(Figure S5A). Studies of hepatic gene expression demonstrated
that the Jnk1D/D Jnk2/ liver exhibited defects in the Con A-
induced expression of several AP1-related genes (Figure 1D).
This observation suggested that the Jnk1D/D Jnk2/ liver might
exhibit profound defects in AP1-dependent gene expression.
Indeed, expression of the AP1 target gene Tnfa was profoundly
reduced in the liver of Con A-treated JNK1/2-deficient mice
(Figure 1D). This loss of TNF-a expression was confirmed by
measurement of the concentration of serum cytokines. Con A
induced the expression ofmany cytokines in the serum of control
mice, but JNK1/2-deficient mice exhibited major defects in
serum cytokine expression, including TNF-a (Figure 2).
The protection ofMx1-Cre+ Jnk1f/f Jnk2/mice against hepa-
titis (Figures 1 and S2) was confirmed by studies using the LPS
model of hepatitis. JNK1/2 deficiency prevented LPS-induced
hepatic damage detected by histological analysis of liver
sections (Figures S2D and S6A), and measurement of serum
transaminase activity (Figure S6B). Decreased expression of
AP1-related genes and Tnfa mRNA in the liver (Figure S6D) and
decreased amounts of serum TNF-a were also detected in the
JNK1/2-deficient mice (Figure S6E). The JNK1/2-deficient mice
also exhibited reduced mortality compared with control mice in
the response to LPS challenge (Figure S7A). Together, these
Figure 1. JNK-Deficient Mice Are Protected
against Con A-Induced Hepatitis
(A) Poly-IC-treated control mice (Mx1-Cre+) and
JNK-deficient mice (Jnk1f/f Jnk2/ Mx1-Cre+)
were aged 4 weeks and then treated intravenously
(8 hr) with Con A or solvent (saline). Liver extracts
were examined by immunoblot analysis using anti-
bodies to JNK1/2, cFLIP, and a-tubulin.
(B) Representative hematoxylin and eosin (H&E)-
stained liver sections prepared from control and
JNK1/2-deficient mice treated (8 hr) with Con A
or solvent (saline) are presented. The amount of
liver damage was quantitated (Figure S2C).
(C) Serum transaminase activity in control and
JNK1/2-deficient mice treated (8 hr) with Con A
or solvent (saline) was measured (mean ± SD;
n = 6). Statistically significant differences between
wild-type and JNK1/2-deficient mice are indicated
(*p < 0.01).
(D) RNA was isolated from the liver of control and
JNK1/2-deficient mice treated (8 hr) with Con A
or solvent (saline). The expression of mRNA was
measured by quantitative real-time PCR assays.
The mRNA expression was normalized to the
amount of Gapdh mRNA and presented as the
mean ± SD (n = 6). Statistically significant differ-
ences between wild-type and JNK1/2-deficient
mice are indicated (*p < 0.01).
data indicate that compound deficiency
of both JNK1 and JNK2 caused strong
protection against two different models
of hepatitis that are induced by treatment
of mice with Con A or LPS, respectively.
JNK Deficiency in Hepatocytes
Does Not Protect Mice against
Hepatitis
The observation that compound mutation
of Jnk1 and Jnk2 causes protection
against both Con A- and LPS-induced
hepatitis (Figures1,S2, andS6) suggested
that JNK1 and JNK2 play redundant roles during progression of
the disease process. It has been proposed that these models of
hepatitis are mediated by TNF-a-induced and JNK-mediated
phosphorylation andactivationof theE3 ligase Itchand the subse-
quent ubiquitin-mediateddegradationof thecaspase8antagonist
cFLIP in hepatocytes (Chang et al., 2006). To test this hypothesis,
we examined cFLIP in control and JNK1/2-deficient liver of mice
treatedwithConA;nochanges incFLIPexpressionweredetected
(Figure1A). Incontrast, treatmentwithLPSdidcausecFLIPdegra-
dation, but this degradation of cFLIP was JNK independent
(Figure S6C). The observation that LPS, but not Con A, caused
cFLIP degradation might reflect the more potent effects of LPS
on hepatitis compared with Con A. Together, these observations
indicate that JNK-mediated cFLIP degradation is not required
for murine models of hepatitis caused by Con A or LPS.
To test the role of JNK in hepatocytes, we examined the effect
of hepatocyte-specific JNK deficiency using Alb-Cre transgenic
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mice. Immunoblot analysis of liver extracts prepared fromcontrol
(Alb-Cre+) mice and JNK-deficient (Alb-Cre+ Jnk1f/f Jnk2/)
mice demonstrated that very low amounts of JNK were detected
in JNK-deficient liver (Figure 3A). The presence of low levels of
JNK in the Alb-Cre deleted mice is consistent with the finding
that the Alb-Cre transgene is selectively expressed in hepato-
cytes, but not in other liver cell-types, including stellate cells,
endothelial cells, NK cells, NKT cells, and Kupffer cells (Postic
et al., 1999). Control studies demonstrated that hepatocyte-
specific JNK1/2 deficiency caused markedly reduced hepatic
JNK activity (monitored by measurement of phospho-Ser73
c-Jun) in mice treated with Con A or LPS (Figures 4B and S8B).
Treatment with Con A caused similar hepatic damage in
control and hepatocyte-specific JNK1/2-deficient mice (Figures
3B and S2C). No differences in TUNEL staining of liver sections
of the control and JNK1/2-deficient mice were detected (Fig-
ure 3C). Similarly, no significant difference in serum transami-
nase activity between the control and JNK1/2-deficient mice
was observed (Figure 3D). The JNK1/2-deficient mice and
control mice also exhibited similar mortality in response to the
Con A challenge (Figure S5B). Gene expression analysis in
JNK1/2-deficient mice did not indicate a consistent loss of
AP1-related gene expression, p53-pathway-related gene
expression, or Tnfa mRNA expression in the liver compared
with control mice (Figure 3E). Measurement of serum cytokines
demonstrated that JNK1/2 deficiency in hepatocytes did not
cause decreased expression of TNF-a or other cytokines exam-
ined in Con A-treated mice (Figure 4A).
Our analysis of Con A-treated mice demonstrated that JNK
expression in hepatocytes is not required for the development
of hepatitis (Figures 3, S2C, and S5B). This conclusion was
confirmed by studies of LPS-induced hepatitis (Figures 5 and
S7A). LPS caused similar hepatic damage in control and hepato-
cyte-specific JNK1/2-deficient mice that was detected by histo-
logical analysis of liver sections (Figure 5A), TUNEL labeling
of apoptotic cells in liver sections (Figure 5A), and serum trans-
aminase activity (Figure 5B). Furthermore, JNK1/2 deficiency
in hepatocytes did not cause changes in the LPS-induced
expression of AP1-related genes, p53-pathway-related genes,
or Tnfa mRNA in liver (Figure 5E). LPS also caused a similar
increase in the serum concentration of TNF-a in mice with
JNK1/2-deficient hepatocytes and control mice (Figure 5C and
Figure 2. JNK-Deficient Mice Exhibit Defects in the Expression of Serum Cytokines
Poly-IC-treated control mice (Mx1-Cre+) and JNK-deficient mice (Jnk1f/f Jnk2/ Mx1-Cre+) were aged 4 weeks and then treated intravenously with Con A. The
amount of serum cytokines after treatment with Con A was measured by ELISA (mean ± SD; n = 7). Statistically significant differences between wild-type and
JNK1/2-deficient mice are indicated (*p < 0.05; **p < 0.01).252 Cell 136, 249–260, January 23, 2009 ª2009 Elsevier Inc.
Figure 3. JNK Deficiency in Hepatocytes Does Not Protect Mice against Con A-Induced Hepatitis
(A) Liver extracts prepared from control mice (Alb-Cre+) and mice with hepatocyte-specific JNK-deficiency (Jnk1f/f Jnk2/ Alb-Cre+) were examined by
immunoblot analysis using antibodies to JNK1/2 and a-tubulin.
(B andC) Control mice (Alb-Cre+) and JNK-deficientmice (Jnk1f/f Jnk2/Alb-Cre+) were treated intravenously (8 hr) with ConA or solvent (saline). Representative
H&E-stained (B) and TUNEL-stained (C) liver sections prepared from control and JNK1/2-deficient mice are presented.
(D) Serum transaminase activity in control and JNK-deficient mice after treatment (8 hr) with Con A or solvent (saline) was measured (mean ± SD; n = 6). No
statistically significant differences between wild-type and JNK1/2-deficient mice were detected.
(E) RNA was isolated from the liver of control and JNK-deficient mice after treatment (8 hr) with ConA or solvent (saline). The expression of mRNA was measured
by quantitative RT-PCR assays (Taqmanª). The mRNA expression was normalized to the amount of Gapdh mRNA and presented as the mean ± SD (n = 6). No
statistically significant differences between wild-type and JNK1/2-deficient mice were detected.S8A). Moreover, cFLIP expression in LPS-treated mice was not
affected by hepatocyte-specific deficiency of JNK1/2 (Figure 5D).
These data demonstrate that there is no critical role of JNK in
hepatocytes for the development of hepatitis, including treat-
ment with Con A or LPS (Figures 3, 5, S2C, and S2D). This finding
contrasts with conclusions drawn from previous studies that
have suggested an essential role of JNK in hepatocytes for
Con A-induced hepatitis (Chang et al., 2006; Kamata et al.,
2005; Maeda et al., 2003).
JNK Is Required for TNF-a Expression but Is Not
Required for TNF-a-Induced Hepatic Damage
The requirement of JNK for hepatocyte death during the devel-
opment of hepatitis (Figures 1 and S6) is not mediated by the
function of JNK in hepatocytes (Figures 3–5). These data suggestthat JNK plays a non-cell autonomous essential role. We consid-
ered several possible mechanisms. The simplest possibility was
a requirement of JNK for Con A- and LPS-induced expression of
inflammatory cytokines by cells that are not hepatocytes. This is
consistent with the finding thatMx1-Cre+ JNK1/2-deficient mice,
which are protected against Con A- and LPS-induced hepatitis
(Figures 1, S2C, S2D, and S6), exhibit defects in the expression
of inflammatory cytokines, including TNF-a (Figures 1D, 2, S6D,
and S6E). In contrast, hepatocyte-specific JNK1/2 deficiency did
not protect against hepatitis and did not cause marked changes
in inflammatorycytokineexpression (Figures4A,5C,5E, andS8A).
To test whether JNK is required for inflammatory cytokine
expression, we prepared in vitro primary cultures of bone-
marrow-derived macrophages from poly-IC-treated control
(Mx1-Cre) and JNK1/2-deficientmice (Mx1-Cre+ Jnk1f/f Jnk2/).Cell 136, 249–260, January 23, 2009 ª2009 Elsevier Inc. 253
Figure 4. Effect of Hepatocyte-Specific JNK Deficiency on Serum Cytokine Expression
(A) Control mice (Alb-Cre+) and mice with hepatocyte-specific JNK deficiency (Jnk1f/f Jnk2/ Alb-Cre+) were treated intravenously with Con A. The amount of
serum cytokines (IL-1, IL-2, IL-4, IL-5, IL-6, IL-10, IL-12, GM-CSF, TNF-a, and IFN-g) after treatment with Con A was measured by ELISA (mean ± SD; n = 8).
Statistically significant differences between wild-type and JNK1/2-deficient mice are indicated (*p < 0.05).
(B) The amount of total and phospho-c-Jun, ERK, p38 MAPK, and AKT in liver extracts at 8 hr after treatment of mice with Con A or saline was measured by
multiplexed ELISA (mean ± SD; n = 5). Statistically significant differences between wild-type and JNK1/2-deficient mice are indicated (*p < 0.01).No JNK was detected in the JNK1/2-deficient macrophages by
immunoblot analysis (Figure 6A). Treatment with Con A demon-
strated increased concentrations of cytokines (TNF-a and IL-6)
in the culture medium of control macrophages (Figure 6B). The
amount of these cytokines in the culture medium of JNK1/2-defi-
cient macrophages was markedly suppressed (Figure 6B). In
contrast, JNK1/2 deficiency did not alter the expression of
IL-10 (Figure 6B). Similarly, JNK1/2-deficient T cells exhibited
defects in Con A-stimulated expression of TNF-a (Figure S4).
Together, these data demonstrate that JNK1/2 is required for
the expression of the inflammatory cytokine TNF-a.
If the essential role of JNK in hepatitis (Figures 1 and S6)
reflects a requirement of JNK for the expression of inflammatory
cytokines (Figures 2, 6B, and S4), then it would be predicted that
the defect in hepatitis caused by JNK deficiency would be com-
plemented by treatment of mice with TNF-a. We detected no
significant difference between control and JNK-deficient mice
in TNF-a-induced serum transaminase activity (Figure 6E) and
mortality (Figure S7B). Immunoblot analysis demonstrated that
TNF-a caused similar caspase 3 activation and PARP cleavage
in the liver of control mice, Mx1-Cre+ JNK1/2-deficient mice,
and Alb-Cre+ JNK1/2-deficient mice (Figures 6C and 6D). These
data confirm that the essential role of JNK1/2 for hepatitis is
mediated by a requirement of JNK1/2 for inflammatory cytokine
expression, including TNF-a, and does not reflect a role for JNK
in TNF-a-stimulated hepatocyte death.
The pro-death role of inflammatory cytokines in hepatitis is
opposed by factors that sustain cell survival. One example is
the role of IL-22 to activate the Stat3 and AKT signaling pathways
in hepatocytes. Indeed, loss of IL-22 expression increases Con254 Cell 136, 249–260, January 23, 2009 ª2009 Elsevier Inc.
Figure 5. JNK Deficiency in Hepatocytes Does Not Protect Mice against LPS-Induced Hepatitis
(A) Control mice (Alb-Cre+) and mice with hepatocyte-specific JNK deficiency (Jnk1f/f Jnk2/ Alb-Cre+) were treated intravenously (8 hr) with LPS plus GalN or
solvent (saline). Representative H&E- and TUNEL-stained liver sections prepared from control and JNK-deficient mice are presented.
(B) Serum transaminase activity in control and JNK1/2-deficient mice after treatment (8 hr) with LPS/GalN or solvent (saline) wasmeasured (mean ± SD; n = 6). No
statistically significant differences between wild-type and JNK1/2-deficient mice were detected.
(C) The concentration of TNF-a in the serum of control mice (Alb-Cre+) and JNK1/2-deficient mice (Jnk1f/f Jnk2/ Alb-Cre+) was measured after treatment (1 hr)
with LPS/GalN or solvent (saline) by ELISA (mean ±SD; n = 6). No statistically significant differences betweenwild-type and JNK1/2-deficientmicewere detected.
(D) Liver extracts prepared from control mice (Alb-Cre+) and JNK1/2-deficient mice (Jnk1f/f Jnk2/ Alb-Cre+) were examined by immunoblot analysis using
antibodies to cFLIP and a-tubulin.
(E) RNA was isolated from the liver of control and JNK-deficient mice after treatment (8 hr) with LPS/GalN or solvent (saline). The expression of mRNA was
measured by quantitative RT-PCR assays. The mRNA expression was normalized to the amount of Gapdh mRNA and presented as the mean ± SD (n = 6).
No statistically significant differences between wild-type and JNK1/2-deficient mice were detected.A-induced hepatitis (Zenewicz et al., 2007). Altered expression of
IL-22 might therefore contribute to the effects of JNK1/2-defi-
ciency onCon A-induced hepatitis. However, no significant differ-
ence in IL-22expressionwasdetectedbetweencontrol andJNK1/
2-deficient mice (Figure S9). Together, these data indicate that IL-
22 does notmediate the effects of JNK1/2 deficiency on hepatitis.
JNK Is Required for TNF Expression
by Hematopoietic Cells
Hematopoietic cells represent one source of the inflammatory
cytokines that might cause hepatitis after treatment with Con Aor LPS (Dong et al., 2007). To test the role of hematopoietic cells,
we constructed radiation chimeras by transplantation of control
(Mx1-Cre+) and JNK1/2-deficient (Mx1-Cre+ Jnk1f/f Jnk2/)
bone marrow from poly-IC-treated donor mice into lethally irradi-
ated congenic recipient mice. Efficient reconstitution of B6.SJL
(CD45.1) mice with Jnk1+/+ Jnk2+/+ or Jnk1D/D Jnk2/ bone
marrow fromC57BL/6J (CD45.2) mice was confirmed by staining
peripheral blood leukocytes with antibodies to CD45.1/CD45.2
and analysis by flow cytometry. Indeed, competitive repopulation
assays demonstrated that mice, reconstituted with an equal
number of wild-type B6.SJL plus Jnk1D/D Jnk2/ or Jnk1+/+Cell 136, 249–260, January 23, 2009 ª2009 Elsevier Inc. 255
Jnk2+/+ C57BL/6J bone marrow cells, displayed similar numbers
ofCD45.1andCD45.2peripheral blood leukocytes6monthsafter
transplantation (Figure 7A). Together, these data demonstrate
that JNK1 and JNK2 are not essential for the repopulation of the
hematopoietic compartment after bone marrow transplantation.
Radiation chimeras with Jnk1+/+ Jnk2+/+ or Jnk1D/D Jnk2/
hematopoietic cells in the blood were identified by quantitative
real-time PCR (RT-PCR) analysis of Jnk1 mRNA expression
(Figure 7B), by PCR analysis of genomic DNA (Figure 7C), and
by immunoblot analysis using a JNK antibody (Figure 7D). Flow
cytometry analysis of splenocytes demonstrated similar
numbers of CD4 T cells, CD8 T cells, and B cells inmice reconsti-
tutedwith control and JNK1/2-deficient bonemarrow (Figure 7E).
Long-lived resident hematopoietic cells in the liver are slowly
replaced after bonemarrow transplantation; therefore, we exam-
ined mice 6 months after transplantation (Alves-Guerra et al.,
2003). Treatment of the radiation chimeras transplanted with
Jnk1+/+ Jnk2+/+ bone marrow demonstrated that treatment
with Con A caused hepatic damage, including increased
amounts of serum transaminase activity (Figure 7F). In contrast,
radiation chimeras transplanted with Jnk1D/D Jnk2/ bone
marrow were protected against hepatic damage caused by
Con A, including reduced amounts of serum transaminase
activity (Figure 7F), and decreased amounts of Tnfa mRNA in
the liver and TNF-a protein expression in blood (Figure 7G).
Together, these data confirm that JNK1/2 in hematopoietic cells
is required for the development of hepatitis.
DISCUSSION
The results of our study demonstrate that JNK is essential for the
development of hepatitis in mouse models. This finding is
Figure 6. JNK Deficiency Inhibits TNF-a Expression but Not TNF-a-Induced Liver Damage
(A,B) Bone-marrow-derived macrophages prepared from poly-IC-treated control mice (Mx1-Cre+) and JNK-deficient mice (Jnk1f/f Jnk2/ Mx1-Cre+) were
examined by immunoblot analysis using antibodies to JNK1/2 and a-tubulin. The macrophages were treated with Con A and cytokines in the culture medium
were measured by ELISA (mean ± SD; n = 7). Statistically significant differences between wild-type and JNK1/2-deficient mice are indicated (*p < 0.01).
(C,D) Poly-IC-treated control mice (Mx1-Cre+) and JNK-deficient mice (Jnk1f/f Jnk2/Mx1-Cre+) (C) or control mice (Alb-Cre+) andmicewith hepatocyte-specific
JNK-deficiency (Jnk1f/f Jnk2/ Alb-Cre+) (D) were treated intravenously (8 hr) with TNF-a plus GalN or solvent (saline). Liver extracts were examined by immu-
noblot analysis using antibodies to caspase-cleaved PARP, cleaved caspase 3, and a-tubulin.
(E) Serum transaminase activity in control and JNK1/2-deficient mice after treatment (8 hr) with LPS/GalN or solvent (saline) wasmeasured (mean ± SD; n = 6). No
statistically significant differences between wild-type and JNK1/2-deficient mice were detected.256 Cell 136, 249–260, January 23, 2009 ª2009 Elsevier Inc.
Figure 7. JNK Deficiency in Hematopoietic Cells Protects Mice against Hepatitis
(A) Competitive bone marrow transplantation assays were performed using lethally irradiated wild-type B6.SJL mice transplanted with an equal number of bone
marrow cells isolated from poly-IC-treated (4 weeks) control B6.SJL (CD45.1) mice plus Jnk1f/f Jnk2/ Mx1-Cre+ or wild-type Mx1-Cre+ C57BL/6J (CD45.2)
mice. Peripheral blood leukocytes were stained with antibodies to CD45.1 and CD45.2 at 6 months after transplantation by flow cytometry (mean ± SD; n = 3).
(B–E) Lethally irradiated wild-type mice were transplanted with bone marrow from poly-IC-treated control mice (Mx1-Cre+) or JNK1/2-deficient mice (Jnk1f/f
Jnk2/Mx1-Cre+) mice. Peripheral blood leukocytes were isolated and Jnk1mRNA was examined by quantitative Taqmanª RT-PCR analysis (B) and genomic
DNA was genotyped by PCR analysis using amplimers to detect the Jnk1+, Jnk1f, and Jnk1D alleles (C). Splenocytes were examined by immunoblot analysis
using antibodies to JNK1/2 and ERK1/2 (D) and subpopulations of splenocytes were examined by flow cytometry (E).
(F) Mice at 6 months after transplantation were treated intravenously (8 hr) with Con A or solvent (saline) and serum transaminase activity (ALT and AST) was
measured (mean ± SD; n = 6). Statistically significant differences between mice transplanted with control and JNK1/2-deficient bone marrow are indicated
(*p < 0.01).
(G) Mice at 6 months after transplantation were treated intravenously with Con A or solvent (saline). The expression of Gapdh, and Tnfa mRNA in the liver was
measured by quantitative RT-PCR assays (Taqmanª) at 8 hr after injection (left panel). The mRNA expression in each sample was normalized to the amount of
GapdhmRNA and presented as the mean ± SD (n = 6). The concentration of TNF-a in the blood wasmeasured at 1 hr after injection by ELISA and is presented as
the mean ± SD (n = 7) (right panel). Statistically significant differences between mice transplanted with control and JNK1/2-deficient bone marrow are indicated
(*p < 0.01).important because of the implication that JNK might be a useful
target for drug therapy for some forms of hepatitis in humans.
Indeed, drugs with specificity for JNK are currently under clinical
development (Manning and Davis, 2003). However, an unex-
pected finding of this study was that JNK appears to play no
role in hepatocytes, but JNK is essential for TNF-a expression
by hematopoietic cells. Therefore, measurement of TNF-amight
serve as a relevant biomarker that is useful for monitoring
the efficacy of JNK inhibition in protocols using JNK inhibitors
in humans.
JNK Is Not Essential for TNF-Stimulated Cell
Death of Hepatocytes
It has previously been reported that JNK is required for TNF-
a-stimulated cell death. Thus, partial JNK deficiency caused by
disruption of the Jnk1 or Jnk2 genes has been reported to reduce
TNF-stimulated apoptosis by unknown mechanisms (Dietrich
et al., 2004; Kamata et al., 2005; Liu et al., 2004; Maeda et al.,
2003; Wang et al., 2006). Furthermore, partial JNK deficiency
has been reported to cause reduced JNK-mediated phosphory-
lation of the E3 ligase Itch, failure to ubiquitinate and degrade theCell 136, 249–260, January 23, 2009 ª2009 Elsevier Inc. 257
caspase 8 antagonist cFLIP, and protection against TNF-stimu-
lated cell death in the Con A model of murine hepatitis (Chang
et al., 2006). However, it is difficult to interpret the results of these
studies because it is established that partial JNK deficiency
results in adaptation and a gain-of-function phenotype caused
by the remaining JNK isoforms (Jaeschke et al., 2006).
Here we report the analysis of compound mutation of the two
ubiquitously expressed genes that encode JNK. The absence
of a requirement of JNK for TNF-a-stimulated hepatocyte
apoptosis is consistent with our previous analysis of TNF-a-stim-
ulated JNK1/2-deficient primary murine embryo fibroblasts
(Lamb et al., 2003), and is also consistent with our finding that
apoptosis caused by a different death receptor ligand (FasL) is
also JNK independent (Tournier et al., 2000).
JNK Is Required for TNF-a Expression
The expression of TNF-a is regulated at multiple steps, including
Tnfa gene transcription, Tnfa mRNA stability, and Tnfa mRNA
translation (Han et al., 1990; Tsai et al., 2000). The ERK and
p38 MAP pathways are implicated in the regulation of Tnfa
mRNA stability and translation (Dumitru et al., 2000; Hitti et al.,
2006) and it is established that JNK plays an important role in
Tnfa gene transcription (Ventura et al., 2003). The Tnfa gene
contains JNK-responsive promoter elements that are required
for normal Tnfa gene expression, including a divergent AP1
site that selectively binds heterodimeric complexes of ATF2
and c-Jun (Tsai et al., 2000). JNK can phosphorylate ATF2 and
c-Jun within the NH2-terminal transcription activation domain
leading to increased transcription activity (Davis, 2000). Indeed,
JNK1/2-deficient fibroblasts exhibit a severe defect in Tnfa
mRNA expression (Ventura et al., 2003) and JNK1/2-deficient
macrophages and T cells express profoundly reduced amounts
of TNF-a in the culture medium (Figures 6B and S4).
Role of JNK in Immune Cells in the Liver
JNK is required for the production of TNF-a by hematopoietic
cells for the development of hepatitis. Because membrane-
bound TNF-a, but not soluble TNF-a, is required for Con
A-induced hepatitis (Kusters et al., 1997), it is likely that the
hematopoietic cells that are the source of JNK-dependent
TNF-a expression include resident inflammatory cells in the liver
(e.g., Kupffer cells and NKT cells).
The liver represents the major reservoir of NKT cells in the
body, and these cells are critically important for Con A-induced
hepatitis (Kaneko et al., 2000; Takeda et al., 2000; Tiegs et al.,
1992). Indeed, NKT-cell-mediated expression of TNF-a, IFN-g,
and IL-4 have been implicated in Con A-induced hepatitis (Kus-
ters et al., 1996, 1997; Tagawa et al., 1998). Interestingly, JNK
deficiency causes major defects in the Con A-induced expres-
sion of these cytokines in serum (Figure 2). Infiltration of the liver
by neutrophils and eosinophils after Con A treatment (Bonder
et al., 2004; Hatada et al., 2005; Jaruga et al., 2003; Louis
et al., 2002) and the production of superoxide by Kupffer cells
(Morita et al., 2003) might also contribute to hepatitis develop-
ment. Nevertheless, TNF-a expression by NKT cells is critically
required for ConA-induced hepatitis. Thus, ConA causes greatly
reduced hepatitis in Tnfa/ mice, Tnfr1/ mice, and Tnfr2/
mice (Kusters et al., 1997; Maeda et al., 2003).258 Cell 136, 249–260, January 23, 2009 ª2009 Elsevier Inc.Conclusions
The results of this study demonstrate that JNKplays a critical role
inmousemodels of TNF-a-dependent hepatitis. It is possible that
under some specific conditions, JNK might influence cFLIP
degradation (Chang et al., 2006) or ROS production (Ventura
et al., 2004) during TNF-a-stimulated cell death. However, JNK
is not required for TNF-a-mediated death of hepatocytes in
models of fulminant hepatitis. In contrast, JNK is essential for
the expression of TNF-a by hematopoietic cells that promote
hepatitis.
EXPERIMENTAL PROCEDURES
Mice
We have previously described Jnk1/ mice (Dong et al., 1998), Jnk2/ mice
(Yang et al., 1998), and Jnk1f/f mice (Das et al., 2007). The JNK knockout mice
were maintained on a C57BL/6J mouse strain background (backcrossed ten
generations). Alb-Cre mice (Postic et al., 1999), Mx1-Cre mice (Kuhn et al.,
1995), B6.SJL mice, and C57BL/6J mice were obtained from The Jackson
Labs. The mice were housed in a facility accredited by the American Associa-
tion for Laboratory Animal Care (AALAC). Deletion of floxed alleles inMx1-Cre
mice was performed by treatment of 4-week-old mice with 20 mg/g poly-IC
(Mikkola et al., 2003) followed by recovery (4 weeks). Genomic DNA was
examined using PCR amplimers (50-CTCAGGAAGAAAGGGCTTATTTC-30
and 50-GAACCACTGTTCCAATTTCCATCC-30) to distinguish between the
wild-type (Jnk1+), floxed (Jnk1f), and deleted (Jnk1D) alleles (Das et al.,
2007). Radiation chimeras using congenic C57BL/6J and B6.SJL mice were
generated by exposure of recipient mice to two doses of ionizing radiation
(525 Gy) and reconstitution of the mice with 107 donor bone marrow cells by
injection into the tail vein. We examined three models of murine hepatitis using
intravenous injection of: (a) 25mg/kg Con A (Sigma); (b) 35 mg/kg E. coli 0111:B
LPS (Sigma) plus 1 g/kg N-acetyl-galactosamine (GalN) (Sigma); and (c) 20 mg/
kg TNF-a (R&D Systems) plus 1 g/kg GalN. The animal studies were approved
by the Institutional Animal Care and Use Committee (IACUC) of the University
of Massachusetts Medical School.
Serum Analysis
Alanine transaminase (ALT) and aspartate aminotransferase (AST) activity in
serum was measured using the ALT and AST Reagent kit (Pointe Scientific)
with a Tecan Sapphire microplate reader (Tecan Trading AG). The serum
concentration of cytokines was measured by multiplexed enzyme-linked
immunosorbent assay (ELISA) using a Luminex 200 instrument (Millipore).
Biochemical Analysis
Immunoblot analysis was performed by probing with antibodies to ERK1/2
(Santa Cruz), JNK1/2 (PharMingen), cFLIP (Alexis), cleaved PARP, cleaved
caspase 3 (Cell Signaling), and a-tubulin (Sigma). The amount of total and
phospho-JNK1/2, c-Jun, ERK1/2, p38 MAPK, and AKT in tissue extracts
was measured by multiplexed ELISA using a Luminex 200 instrument
(Millipore). The expression of mRNA was examined by quantitative RT-PCR
analysis using a 7500 Fast Real Time PCR machine. Taqman assays (Applied
Biosystems).
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